Autoantibodies in diabetes.
Pihoker, C ; Gilliam, L K ; Hampe, C S and Lernmark, Åke LU
(2005)
In Diabetes
54(Dec).
p.52-61
- Abstract
- Islet cell autoantibodies are strongly associated with the development of type 1 diabetes. The appearance of autoantibodies to one or several of the autoantigens—GAD65, IA-2, or insulin—signals an autoimmune pathogenesis of ß-cell killing. A ß-cell attack may be best reflected by the emergence of autoantibodies dependent on the genotype risk factors, isotype, and subtype of the autoantibodies as well as their epitope specificity. It is speculated that progression to ß-cell loss and clinical onset of type 1 diabetes is reflected in a developing pattern of epitope-specific autoantibodies. Although the appearance of autoantibodies does not follow a distinct pattern, the presence of multiple autoantibodies has the highest positive predictive... (More)
- Islet cell autoantibodies are strongly associated with the development of type 1 diabetes. The appearance of autoantibodies to one or several of the autoantigens—GAD65, IA-2, or insulin—signals an autoimmune pathogenesis of ß-cell killing. A ß-cell attack may be best reflected by the emergence of autoantibodies dependent on the genotype risk factors, isotype, and subtype of the autoantibodies as well as their epitope specificity. It is speculated that progression to ß-cell loss and clinical onset of type 1 diabetes is reflected in a developing pattern of epitope-specific autoantibodies. Although the appearance of autoantibodies does not follow a distinct pattern, the presence of multiple autoantibodies has the highest positive predictive value for type 1 diabetes. In the absence of reliable T-cell tests, dissection of autoantibody responses in subjects of genetic risk should prove useful in identifying triggers of islet autoimmunity by examining seroconversion and maturation of the autoantibody response that may mark time to onset of type 1 diabetes. The complexity of the disease process is exemplified by multiple clinical phenotypes, including autoimmune diabetes masquerading as type 2 diabetes in youth and adults. Autoantibodies may also provide prognostic information in clinically heterogeneous patient populations when examined longitudinally. (Less)
Please use this url to cite or link to this publication:
https://lup.lub.lu.se/record/1133063
- author
- Pihoker, C
; Gilliam, L K
; Hampe, C S
and Lernmark, Åke
LU
- publishing date
- 2005
- type
- Contribution to journal
- publication status
- published
- subject
- in
- Diabetes
- volume
- 54
- issue
- Dec
- pages
- 52 - 61
- publisher
- American Diabetes Association Inc.
- external identifiers
-
- scopus:33644750399
- ISSN
- 1939-327X
- language
- English
- LU publication?
- no
- id
- 02e34b0a-d443-4850-bfc7-4dd673c30cc9 (old id 1133063)
- alternative location
- http://diabetes.diabetesjournals.org/cgi/content/full/54/suppl_2/S52
- date added to LUP
- 2016-04-01 15:32:43
- date last changed
- 2023-03-27 04:36:58
@article{02e34b0a-d443-4850-bfc7-4dd673c30cc9,
abstract = {{Islet cell autoantibodies are strongly associated with the development of type 1 diabetes. The appearance of autoantibodies to one or several of the autoantigens—GAD65, IA-2, or insulin—signals an autoimmune pathogenesis of ß-cell killing. A ß-cell attack may be best reflected by the emergence of autoantibodies dependent on the genotype risk factors, isotype, and subtype of the autoantibodies as well as their epitope specificity. It is speculated that progression to ß-cell loss and clinical onset of type 1 diabetes is reflected in a developing pattern of epitope-specific autoantibodies. Although the appearance of autoantibodies does not follow a distinct pattern, the presence of multiple autoantibodies has the highest positive predictive value for type 1 diabetes. In the absence of reliable T-cell tests, dissection of autoantibody responses in subjects of genetic risk should prove useful in identifying triggers of islet autoimmunity by examining seroconversion and maturation of the autoantibody response that may mark time to onset of type 1 diabetes. The complexity of the disease process is exemplified by multiple clinical phenotypes, including autoimmune diabetes masquerading as type 2 diabetes in youth and adults. Autoantibodies may also provide prognostic information in clinically heterogeneous patient populations when examined longitudinally.}},
author = {{Pihoker, C and Gilliam, L K and Hampe, C S and Lernmark, Åke}},
issn = {{1939-327X}},
language = {{eng}},
number = {{Dec}},
pages = {{52--61}},
publisher = {{American Diabetes Association Inc.}},
series = {{Diabetes}},
title = {{Autoantibodies in diabetes.}},
url = {{http://diabetes.diabetesjournals.org/cgi/content/full/54/suppl_2/S52}},
volume = {{54}},
year = {{2005}},
}